Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012

  Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart
                     Association Scientific Sessions 2012

PR Newswire

THOUSAND OAKS, Calif., Nov. 2, 2012

THOUSAND OAKS, Calif., Nov. 2, 2012 /PRNewswire/ --Amgen (NASDAQ:AMGN) will
present data from four Phase 2 trials of AMG 145, an investigational fully
human monoclonal antibody directed against PCSK9, a protein that reduces the
liver's ability to remove low density lipoprotein cholesterol (LDL-C), or
"bad" cholesterol from the blood, at the upcoming American Heart Association
(AHA) Scientific Sessions 2012.

Selected abstracts of interest that will be presented at the meeting include:

  oReduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial
    Hypercholesterolemia Disorder (RUTHERFORD): Results from a Phase 2,
    Randomized, Double-Blind, Placebo-Controlled Trial
    Late-Breaking Clinical Trials, Monday, Nov. 05, 10:50 a.m. – 11:00 a.m.
    (Hall G)

  oGoal Achievement after Utilizing an Anti-PCSK9 in Statin Intolerant
    Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo
    controlled Study
    Late-Breaking Clinical Trials, Monday, Nov. 05, 11:00 a.m. – 11:10 a.m.
    (Hall G)

  oLAPLACE-TIMI 57 Primary Results
    Clinical Science: Special Reports, Tuesday, Nov. 06, 7:45 a.m. – 7:55 a.m.
    (Petree Hall D)

  oEfficacy and Safety of a Fully Human Monoclonal Antibody Against PCSK9 as
    Monotherapy for Hypercholesterolemia: Results from the MENDEL Study, a
    Global Phase 2 Trial of AMG 145
    Clinical Science: Special Reports, Tuesday, Nov. 06, 7:55 a.m. – 8:05 a.m.
    (Petree Hall D)

AboutAmgen

Amgendiscovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980,Amgenwas one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient.Amgentherapeutics have
changed the practice of medicine, helping millions of people around the world
in the fight against cancer, kidney disease, rheumatoid arthritis, bone
disease and other serious illnesses. With a deep and broad pipeline of
potential new medicines,Amgenremains committed to advancing science to
dramatically improve people's lives. For more information, visit
www.amgen.comand follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC) reports filed
byAmgen, includingAmgen's most recent annual report on Form 10-K and most
recent periodic reports on Form 10-Q and Form 8-K. Please refer toAmgen's
most recent Forms 10-K, 10-Q and 8-K for additional information on the
uncertainties and risk factors related to our business. Unless otherwise
noted,Amgenis providing this information as of Nov. 2, 2012, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us to complete clinical trials and obtain regulatory approval for
product marketing has in the past varied and we expect similar variability in
the future. We develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates that are
derived from relationships may be subject to disputes between the parties or
may prove to be not as effective or as safe as we may have believed at the
time of entering into such relationship. Also, we or others could identify
safety, side effects or manufacturing problems with our products after they
are on the market. Our business may be impacted by government investigations,
litigation and products liability claims. We depend on third parties for a
significant portion of our manufacturing capacity for the supply of certain of
our current and future products and limits on supply may constrain sales of
certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies
imposed by third-party payors, including governments, private insurance plans
and managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed
care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and technology,
the protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates. We cannot guarantee that we will be able to
produce commercially successful products or maintain the commercial success of
our existing products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant problems
with a product similar to one of our products that implicate an entire class
of products could have a material adverse effect on sales of the affected
products and on our business and results of operations.

The scientific information discussed in this news release related to our
product candidates is preliminary and investigative. Such product candidates
are not approved by the U.S. Food and Drug Administration (FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates. Only the FDA can determine whether the product
candidates are safe and effective for the use(s) being investigated.
Healthcare professionals should refer to and rely upon the FDA-approved
labeling for the products, and not the information discussed in this news
release.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-559-0718 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Website: http://www.amgen.com
 
Press spacebar to pause and continue. Press esc to stop.